Tokushima Anti-Oxidation and RAS inhibition Clinical Trial In hypertensives, Cilnidipine versus Amlodipine

Tokushima Anti-Oxidation and RAS inhibition Clinical Trial In hypertensives, Cilnidipine versus Amlodipine - TACTICAL2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006544

Enrollment

200

Registered

2011-11-01

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

cilnidipine (initial dose is 10mg/day 10-20mg is available depending on the blood pressure level) amlodipine (initial dose is 5mg/day, but 5-10mg is available depending on the blood pressure level)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Out patients 2. Patients who received an Antihypertensive treatment with RAS inhibitors. 3. Blood pressure (BP): systolic BP (SBP) 140mmHg and above or diastolic BP (DBP) 90mmHg and above.

Exclusion criteria

Exclusion criteria: 1. Malignant hypertension 2. Pregnant women, or Women suspected of being pregnant. 3. Severe liver disorder. 4. Patients who are inadequate to enter this study due to the other reasons by physician's judgements.

Design outcomes

Primary

Measure	Time frame
1. Clinic blood pressure, heart rate. 2. Home blood pressure, heart rate. 3. urinary 8-OHdG 4. hs-CRP 5. urinary albumin-creatinine ratio. 6. urinary L-FABP. 7. LDL-C, TG, HDL-C, BUN, Cr, HbA1c fasting blood glucose (*Patients with diabetes) 8. PRA, Angiotensin, Aldsterone	—

Countries

Japan

Contacts

Public ContactTakeshi Soeki

The University of Tokushima Institute of Health Biosciences, Graduate School. Cardiovascular Medicine

soeki@tokushima-u.ac.jp088-633-7851

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026